Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Venus Research Center

ClinicalTrials.gov lists Venus Research Center as lead sponsor of 11 trials.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Disease areas Disease areas 4 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Latest dated events Latest dated events 11 Biomarker capability evidence Biomarker capability evidence 4 Disease areas Disease areas 4 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 Latest dated events Latest dated events 11 Biomarker capability evidence Biomarker capability evidence 4

Rows recorded per section

20 sections measured, none recorded

This page covers Venus Research Center: 11 lead-sponsored trials and 0 legal-entity registrations.

Get the Venus Research Center report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (4)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Acne Vulgaris 1
Breast Neoplasms 1
Hyperpigmentation 1
Melanosis 1

Trials by start year as sponsor or collaborator (2)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 6
2025 5

No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Latest dated events (11)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-06-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-05-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-01-25 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-01-25 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-01-25 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (4)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ENAH Trial sponsor Named in trial inclusion criteria
ENAH Trial sponsor Named in trial inclusion criteria
ENAH Trial sponsor Mentioned in trial text
ENAH Trial sponsor Mentioned in trial text

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sponsor delivery record, journals published in, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.